Neurocrine Biosciences | Capitaux D'Emprunt



Loan Capital Changement Date
AbbVie USD 60.34B 1.83B 2024-12
Acadia Pharmaceuticals USD 0 0 2024-12
Agios Pharmaceuticals USD 0 0 2025-03
ALKERMES USD 0 0 2025-03
Alnylam Pharmaceuticals USD 1.03B 945K 2025-03
Amgen USD 54.01B 2.54B 2025-03
Biogen USD 4.55B 1.4M 2024-12
BioMarin Pharmaceutical USD 595.65M 244K 2025-03
Cytokinetics USD 645.6M 1.1M 2024-12
Dynavax Technologies USD 223.85M 293K 2024-12
Exelixis USD 0 0 2025-01
Gilead Sciences USD 24.9B 3.46B 2024-12
Halozyme Therapeutics USD 1.51B 1.65M 2025-03
Incyte USD 32.64M 899K 2025-03
Ionis Pharmaceuticals USD 1.25B 5.23M 2025-03
Neurocrine Biosciences USD 0 0 2024-12
Pfizer USD 57.64B 234M 2025-03
Prothena USD 0 0 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2025-03
Repligen USD 529.6M 4.04M 2025-03
Sarepta Therapeutics USD 1.14B 1.16M 2025-03
Teva Pharmaceutical Industries USD 16.23B 228M 2025-03
Ultragenyx Pharmaceutical USD 0 0 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Neurocrine Biosciences Capitaux D'Emprunt - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.